Peptide-MHC–targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells
Science Advances · 2025
DOI: 10.1126/sciadv.adv2331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Ellen J K Xu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Retroviridae, Lymphocytes, Tumor-Infiltrating, Gene Transfer Techniques, CD8-Positive T-Lymphocytes. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated that endogenous T cells can be harnessed to initiate effective antitumor responses. Despite clinical promise, current TIL production protocols involve weeks-long ex vivo expansions that can affect treatment efficacy. Therefore, additional tools are needed to engineer TILs to have increased potency while mitigating manufacturing challenges. Here, we present a strategy for pseudotyping retroviruses with peptide–major histocompatibility complexes (pMHCs) for antigen-specific gene delivery to CD8 T cells and validate therapeutic impact in immunocompetent mouse models. We demonstrate that pMHC-targeted viruses specifically deliver function-enhancing cargos while simultaneously activating and expanding antitumor T cells. This targeting precision enables in vivo engineering of tumor-specific T cells, resulting in improved overall survival in B16F10-bearing mice. Together, we have established that pMHC-targeted viruses are efficient vectors for reprogramming and expanding tumor-specific T cells directly in vivo, with the potential to substantially streamline engineered cell therapy production.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
- Singapore-MIT Alliance for Research and Technology Centre, Singapore, Singapore.
- Department of Immunology, Harvard Medical School, Boston, MA, USA.
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
ORCID-Profile: Ellen J K Xu, Winiffer D Conce Alberto, Michael J Walsh, Birkley Lim, Megan T Hoffman, Li Qiang, Emma N Finburgh, Jiayi Dong, Andrea Garmilla, Qingyang Henry Zhao, Caleb R Perez, Michael Dougan, Stephanie K Dougan, Michael E Birnbaum
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Xu, E. J. K., Smith, B. E., Conce Alberto, W. D., Walsh, M. J., Lim, B., Hoffman, M. T., Qiang, L., Barreiro, A., Finburgh, E. N., Dong, J., Garmilla, A., Zhao, Q. H., Perez, C. R., Gaglione, S. A., Dobson, C. S., Dougan, M., Dougan, S. K., & Birnbaum, M. E. (2025). Peptide-MHC–targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells. Science Advances. https://doi.org/10.1126/sciadv.adv2331
Vancouver
Xu EJK, Smith BE, Conce Alberto WD, Walsh MJ, Lim B, Hoffman MT, et al. Peptide-MHC–targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells. Science Advances. 2025. doi:10.1126/sciadv.adv2331
BibTeX
@article{Xu2025,
author = {Xu, Ellen J K and Smith, Blake E and Conce Alberto, Winiffer D and Walsh, Michael J and Lim, Birkley and Hoffman, Megan T and Qiang, Li and Barreiro, Ariana and Finburgh, Emma N and Dong, Jiayi and Garmilla, Andrea and Zhao, Qingyang Henry and Perez, Caleb R and Gaglione, Stephanie A and Dobson, Connor S and Dougan, Michael and Dougan, Stephanie K and Birnbaum, Michael E},
title = {Peptide-MHC–targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adv2331}
}
EUVIMED